aTyr Pharma, Inc. (ATYR) Cash Flow Statement
aTyr Pharma, Inc. (ATYR) generated -$54.5M of operating cash flow over the twelve months to 2026-06-30, spent $279000 on capital expenditure and had free cash flow of -$54.8M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ATYRaTyr Pharma, Inc.Follow ATYR — free
—
Price chart with a free account
- Market cap
- 16.2M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
| Line | FY2019 Dec 19 | FY2020 Dec 20 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -20.0 | -15.3 | -41.9 | -33.2 | -69.1 | -62.0 | -54.5 | |
| Capital expenditure | 0.1 | 0.2 | 1.6 | 4.2 | 0.1 | 0.1 | -0.3 | |
| Free cash flow | -20.1 | -15.5 | -43.5 | -37.4 | -69.2 | -62.1 | -54.8 |
USD millions · SEC XBRL
aTyr Pharma, Inc. — questions
- What is aTyr Pharma, Inc.'s operating cash flow?
- -$54.5M over the twelve months to 2026-06-30.
- How much does aTyr Pharma, Inc. spend on capital expenditure?
- $279000 over the twelve months to 2026-06-30.
- What is aTyr Pharma, Inc.'s free cash flow?
- -$54.8M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from aTyr Pharma, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.